BridgeMD
New treatment option for Multiple System Atrophy (MSA)
Official title MSA-01 in Multiple System Atrophy
ClinicalTrials.gov ID: NCT07446894
What this study is testing
What is MSA-01?
MSA-01 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for multiple system atrophy (msa).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to evaluate whether MSA-01 slows the progression of multiple system atrophy (MSA) and to assess its safety. The primary question is: Does MSA-01 slow the progression of motor impairment as measured by UMSARS Part 2 score?
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 79
You may be able to join if
- At the time of informed consent
- Patients diagnosed as 'clinically established' or 'clinically probable' MSA based on the revised MSA diagnostic criteria of the Movement Disorder...
- Patients who are able to walk independently or with the use of assistive devices.
- Patients who are able to attend outpatient visits at the participating study site. At the start of study drug administration
- Patients who are able to discontinue the use of CoQ10 supplements.
You likely can't join if
- Patients with severe neurological disorders, other progressive movement disorders, or cognitive impairment.
- Patients with severe liver disease.
- Patients with a known history of hypersensitivity to any component of the investigational drug.
- Pregnant women, breastfeeding women, or women who may be pregnant.
- Patients who have previously participated in a clinical trial of MSA-01.
The study team makes the final eligibility decision.
Where it's taking place
- Nagoya, Aichi-ken, Japan
- Chiba, Chiba, Japan
- Fukuoka, Fukuoka, Japan
- Sapporo, Hokkaido, Japan
- Kagoshima, Kagoshima-ken, Japan
- Kyoto, Kyoto, Japan
- Okayama, Okayama-ken, Japan
- Hasuda, Saitama, Japan
- Bunkyō-Ku, Tokyo, Japan
- Kodaira, Tokyo, Japan
- Yonago, Tottori, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 years to 79 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nagoya, Aichi-ken, Japan; Chiba, Chiba, Japan; Fukuoka, Fukuoka, Japan; Sapporo, Hokkaido, Japan; Kagoshima, Kagoshima-ken, Japan; Kyoto, Kyoto, Japan and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.